Serum Levels of CA19‐9 in patients with nonmalignant respiratory diseases

Abstract

CA19-9 is a specific tumor marker in patients with gastrointestinal cancer; however, some patients with respiratory disease can have elevated serum levels of CA19-9 as well. In this study we evaluated serum CA19-9 levels of patients with nonmalignant respiratory diseases. We also estimated the prognostic significance of elevated serum levels of CA19-9 in patients with interstitial lung diseases. The study included 554 patients who had been diagnosed at our hospital during the period of 1984-2005. Serum CA19-9 levels in these patients were measured with a commercially available kit. Elevated levels (>37 U/mL) of CA19-9 were observed in 30.7% of patients with lung cancer. Furthermore, 38.9% of patients with idiopathic interstitial pneumonia (IIP), collagen disease-associated pulmonary fibrosis (CDPF), diffuse panbronchiolitis (DPB), and bronchiectasis had elevated serum CA19-9 levels. Survival rates were significantly lower in patients with interstitial lung diseases (IIP and CDPF) and elevated serum CA19-9 levels than in those with levels in the normal range (P=0.0065). Serum CA19-9 was elevated in some patients with nonmalignant diffuse lung diseases. Therefore, clinicians should pay attention to the evidence that increased serum CA19-9 levels can be found in nonmalignant respiratory disease patients. In patients with IIP and CDPF, elevated serum CA19-9 levels may be related to poor prognosis.

Raised serum CEA and CA 19-9 in Lung Cancer in tertiary care hospital in Eastern India

“…High CA 19-9 elevation has been observed in some chronic inflammatory lung diseases, such as intestinal pneumonia, bronchiectasis, diffuse panbronchiolitis etc [21] . In the present study, CA 19-9 was higher in lung cancer subjects while correlation was not there with CEA and thus it is presumed that elevated serum CA 19-9 was associated with the CA 19-9 generated by cancer cells of lung.…”

Pulmonary sequestration associated with significant elevation of serum carbohydrate antigen 19-9: report of two cases

“…CA19-9 is a tumor marker which is not so specific for malignant tumor, which can be found in the normal epithelial lining of the biliary tract, gastric mucosa and pancreatic duct (1), or even respiratory epithelium (2). Some reports showed that the CA19-9 is also produced by the bronchiolar epithelia, as a result of airway damage; it can be elevated in serum (3).…”

Capsule Endoscopy Detection of Ileal Mucosa Alterations due to Cow Milk Malabsorption in a Celiac Patient

“…CA 19-9 is synthesized by normal human pancreatic and biliary ductular cells as well as by gastric, colonic, endometrial, and salivary epithelia [9]. Persistent high serum levels of this cancer marker have also been reported in serum CA 19-9 with no evidence of malignant disease [5] as well as in patients with nonmalignant diffuse lung diseases, such as idiopathic pulmonary fibrosis, bronchiectasis, cystic fibrosis [10] and diabetes mellitus [11]. It has been shown that increased CA 19-9 serum levels are present in patients with hypothyroidism, and the gradual improvement of the thyroid function resulted in the resolution of the elevated CA 19-9 levels [12].…”